Understanding Gut Antibodies in HIV-1 Infection
Official title: The Public Mucosal Antibody Repertoire in HIV-1 Infection
Funded at University of Colorado Denver · NIH-11158681 · Data updated 2026-11-12
This project looks at how special antibodies in the gut might help people living with HIV-1 stay healthier.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project start | August 1, 2024 |
| Project end | June 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $195,000 |
| NIH project number | 5R21AI183981-02 |
| Project ID | NIH-11158681 on NIH RePORTER |
Who could benefit from this research
✓Could help
This research is based on samples from people living with HIV-1 and HIV-1-uninfected individuals.
✕Less likely to help
Patients who do not have HIV-1 or related gut inflammation may not directly benefit from this specific line of research.
What this research studies
People living with HIV-1 often face ongoing inflammation and health issues, even with treatment. This project explores how the gut's natural defenses, specifically certain antibodies, interact with gut bacteria to maintain a healthy balance. Researchers are studying gut tissue samples from people with and without HIV-1 to understand how these antibodies change in HIV-1 infection. The goal is to discover if these 'public' antibodies, which are shared among many people, play a key role in gut health and could be harnessed for new treatments.
Why it matters
Potential benefit: If successful, this work could lead to new ways to reduce inflammation and improve overall health for people living with HIV-1 by strengthening their gut defenses.
How similar studies have gone: While the concept of 'public' antibodies is emerging, this specific application to human HIV-1 gut health is a novel area of exploration.
Where this research is happening
-
University of Colorado Denver
Aurora, United States Active
Researchers
- Principal investigator: Santiago, Mario Luis — University of Colorado Denver
- Study coordinator: Santiago, Mario Luis
Related research
Other NIH-funded projects on the same topics.
-
BEAT-HIV: a collaborative effort to cure HIV with immunotherapy
A multi-institution study is testing a combination immunotherapy approach to achieve long-term HIV remission or cure for people on ART.
-
Phosphatidylserine-targeting antibodies and T cell function in HIV-1 infection
This NIH grant will explore how antibodies that target phosphatidylserine affect immune cells in people living with HIV on ART.
-
Ribosomal frameshifting in HIV-1 infection and its effects on inflammation and brain health
A study at the University of Rochester will explore how HIV-1 may change human cell machinery to boost its own replication and cause inflammation and brain-related problems.
-
Targeting NLRP3 inflammasome to protect HIV patients from stroke
A small NIH grant will explore whether HIV infection makes stroke worse and whether blocking a brain inflammation pathway (NLRP3) could protect brain tissue.
-
Reprogramming tissue immune cells (macrophages) to target hidden HIV
Trying small drug molecules to reprogram tissue immune cells so infected cells die and hidden HIV is reduced in people living with HIV.
-
EHD4 protein and HIV-1 infection: a new potential antiviral target
A study to understand how the human protein EHD4 affects HIV-1 infection and whether it could be targeted to develop better antiviral therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.